<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Atorvastatin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01076</strong>&#160; (APRD00055)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (<span class="caps">HMG</span>-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. <span class="caps">HMG</span>-CoA reductase catalyzes the conversion of <span class="caps">HMG</span>-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01076/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01076/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01076.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01076.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01076.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01076.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01076.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01076">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Lipovastatinklonal</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Atorvastatin Calcium</strong>
          <div class="cas">134523-03-8</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000011/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000011/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: FQCKMBLVYCEXJB-ZUHSGPLBNA-L</li>
              <li>Monoisotopic Mass: 1154.452941981</li>
              <li>Average Mass: 1155.342</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000011">DBSALT000011</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Atogal</td><td>Ingers (Czech Republic)</td></tr><tr><td>Cardyl</td><td>Pfizer (Spain)</td></tr><tr><td>Faboxim</td><td>Fabop (Argentina)</td></tr><tr><td>Hipolixan</td><td>Pasteur (Chile)</td></tr><tr><td>Lipitor</td><td>Pfizer, Elea (Argentina)</td></tr><tr><td>Lipotropic</td><td>Drugtech (Chile)</td></tr><tr><td>Liprimar</td><td>Pfizer (Hungary, Ukraine), Goedecke (Russia)</td></tr><tr><td>Lowden</td><td>Saval (Chile)</td></tr><tr><td>Normalip</td><td>Quesada (Argentina)</td></tr><tr><td>Sincol</td><td>Indeco (Argentina)</td></tr><tr><td>Sortis</td><td>Pfizer (Austria, Czech Republic, Germany, Hungary, Poland, Portugal, Switzerland), Godecke (Germany), Parke, Davis (Germany)</td></tr><tr><td>Torvacard</td><td>Zentiva (Czech Republic, Hungary, Poland, Russia, Ukraine)</td></tr><tr><td>Torvast</td><td>Pfizer (Italy)</td></tr><tr><td>Totalip</td><td>Guidotti (Italy)</td></tr><tr><td>Tulip</td><td>Lek (Czech Republic, Russia), Wermar (Mexico), Sandoz (Poland, Ukraine), Pharmacia (Spain)</td></tr><tr><td>Vastina</td><td>Penn (Argentina)</td></tr><tr><td>Xanator</td><td>Sieger (Greece)</td></tr><tr><td>Xarator</td><td>Parke, Davis (Italy)</td></tr><tr><td>Zurinel</td><td>Prater (Chile)</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Caduet</td><td>atorvastatin calcium, amlodipine besilate</td></tr><tr><td>Liptruzet </td><td>Atorvastatin calcium, ezetimibe </td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anticholesteremic-agents">Anticholesteremic Agents</a></li>
<li><a href="/mesh/hydroxymethylglutaryl-coa-reductase-inhibitors">Hydroxymethylglutaryl-CoA Reductase Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>134523-00-5</td></tr><tr><th>Weight</th><td>Average: 557.6319<br>Monoisotopic: 557.245175413</td></tr><tr><th>Chemical Formula</th><td>C<sub>33</sub>H<sub>34</sub>FN<sub>2</sub>O<sub>5</sub></td></tr><tr><th>InChI Key</th><td>XUKUURHRXDUEBC-UHFFFAOYNA-M</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/p-1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CCC(O)CC(O)CC([O-])=O)C1=CC=C(F)C=C1)C1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Pyrroles</td></tr><tr><th>Subclass</th><td>Substituted Pyrroles</td></tr><tr><th>Direct parent</th><td>Diphenylpyrroles</td></tr><tr><th>Alternative parents</th><td>Stilbenes; Anilides; Pyrrole Carboxamides; Heterocyclic Fatty Acids; Beta Hydroxy Acids and Derivatives; Fluorobenzenes; N-substituted Pyrroles; Aryl Fluorides; Secondary Carboxylic Acid Amides; Secondary Alcohols; Enolates; Carboxylic Acids; Polyamines; Organofluorides</td></tr><tr><th>Substituents</th><td>stilbene; acetanilide; pyrrole-3-carboxamide; pyrrole-3-carboxylic acid or derivative; fluorobenzene; beta-hydroxy acid; hydroxy acid; benzene; n-substituted pyrrole; aryl halide; aryl fluoride; carboxamide group; secondary alcohol; secondary carboxylic acid amide; polyamine; enolate; carboxylic acid; carboxylic acid derivative; alcohol; organonitrogen compound; amine; organohalogen; organofluoride</td></tr><tr><th>Classification description</th><td>This compound belongs to the diphenylpyrroles. These are aromatic heterocyclic compounds whose structure is based on a pyrrole ring linked to exactly two phenyl groups.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>May be used as primary prevention in individuals with multiple risk factors for coronary heart disease (CHD) and as secondary prevention in individuals with CHD to reduce the risk of myocardial infarction (MI), stroke, angina, and revascularization procedures. May be used to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS). May be used in the treatment of primary hypercholesterolemia and mixed dyslipidemia, homozygous familial hypercholesterolemia, primary dysbetalipoproteinemia, and/or hypertriglyeridemia as an adjunct to dietary therapy to decrease serum total and low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apoB), and triglyceride concentrations, while increasing high-density lipoprotein cholesterol (HDL-C) levels.</td></tr><tr><th>Pharmacodynamics</th><td>Atorvastatin, a selective, competitive HMG-CoA reductase inhibitor, is used to lower serum total and LDL cholesterol, apoB, and triglyceride levels while increasing HDL cholesterol. High LDL-C, low HDL-C and high TG concentrations in the plasma are associated with increased risk of atherosclerosis and cardiovascular disease. The total cholesterol to HDL-C ratio is a strong predictor of coronary artery disease and high ratios are associated with higher risk of disease. Increased levels of HDL-C are associated with lower cardiovascular risk. By decreasing LDL-C and TG and increasing HDL-C, atorvastatin reduces the risk of cardiovascular morbidity and mortality. Atorvastatin has a unique structure, long half-life, and hepatic selectivity, explaining its greater LDL-lowering potency compared to other HMG-CoA reductase inhibitors.</td></tr><tr><th>Mechanism of action</th><td>Atorvastatin selectively and competitively inhibits the hepatic enzyme HMG-CoA reductase. As HMG-CoA reductase is responsible for converting HMG-CoA to mevalonate in the cholesterol biosynthesis pathway, this results in a subsequent decrease in hepatic cholesterol levels. Decreased hepatic cholesterol levels stimulates upregulation of hepatic LDL-C receptors which increases hepatic uptake of LDL-C and reduces serum LDL-C concentrations. </td></tr><tr><th>Absorption</th><td>Atorvastatin is rapidly absorbed after oral administration with maximum plasma concentrations achieved in 1 to 2 hours. The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic bioavailability is due to presystemic clearance by gastrointestinal mucosa and first-pass metabolism in the liver. </td></tr><tr><th>Volume of distribution</th><td><p>381 L</p></td></tr><tr><th>Protein binding</th><td>&gt;98% bound to plasma proteins</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Atorvastatin is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products. In vitro inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites. CYP3A4 is also involved in the metabolism of atorvastatin. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Atorvastatin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li></ul></td><td><a href="/metabolites/DBMET00351">para-hydroxyatorvastatin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/353">Details</a></td></tr><tr><td>Atorvastatin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li></ul></td><td><a href="/metabolites/DBMET00352">ortho-hydroxyatorvastatin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/354">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00351">para-hydroxyatorvastatin</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01266">para-hydroxyatorvastatin lactone</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1426">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00352">ortho-hydroxyatorvastatin</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01267">ortho-hydroxyatorvastatin lactone</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1427">Details</a></td></tr><tr><td>Atorvastatin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01268">Atorvastatin lactone</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1428">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Eliminated primarily in bile after hepatic and/or extrahepatic metabolism. Does not appear to undergo significant enterohepatic recirculation. Less than 2% of the orally administered dose is recovered in urine. </td></tr><tr><th>Half life</th><td>14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Generally well-tolerated. Side effects may include myalgia, constipation, asthenia, abdominal pain, and nausea. Other possible side effects include myotoxicity (myopathy, myositis, rhabdomyolysis) and hepatotoxicity. To avoid toxicity in Asian patients, lower doses should be considered. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Effect</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Kinesin-like protein KIF6<br>Gene symbol: KIF6<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/Q6ZMV9" target="_blank">Q6ZMV9 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs20455" target="_blank">rs20455 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>C Allele</td><td>Improved response to statin drugs</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/18222353" target="_blank" title="Iakoubova OA, Tong CH, Rowland CM, Kirchgessner TG, Young BA, Arellano AR, Shiffman D, Sabatine MS, Campos H, Packard CJ, Pfeffer MA, White TJ, Braunwald E, Shepherd J, Devlin JJ, Sacks FM: Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol. 2008 Jan 29;51(4):435-43.">18222353 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>3-hydroxy-3-methylglutaryl-coenzyme A reductase<br>Gene symbol: HMGCR<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P04035" target="_blank">P04035 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs17244841" target="_blank">rs17244841 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>T Allele</td><td>Reduced response to statin drugs</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/15199031" target="_blank" title="Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM: Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA. 2004 Jun 16;291(23):2821-7.">15199031 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Multidrug resistance protein 1<br>Gene symbol: ABCB1<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P08183" target="_blank">P08183 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs1045642" target="_blank">rs1045642 <span class="glyphicon glyphicon-new-window"> </span></a></td><td>MDR1*T</td><td>T Allele (C3435T)</td><td>Larger reduction in LDL and smaller increase in HDL cholesterol in females</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/15081455" target="_blank" title='# Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ: Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am J Cardiol. 2004 Apr 15;93(8):1046-50. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15081455'>15081455 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.8947</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.7825</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8956</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5246</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.7164</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.8724</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8131</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7887</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6841</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8551</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.719</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9042</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6191</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6675</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.6894</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9133
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7777
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9974
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.5686 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9904
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.5101
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Pfizer inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li>Apotheca Inc.</li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Direct Pharmaceuticals Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li>Goedecke GmbH</li>
<li>Healthcare Pharmacy</li>
<li>Heartland Repack Services LLC</li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.orimedical.com">Orifice Medical AB</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li>Tya Pharmaceuticals</li>
<li>US Pharmaceutical Group</li>
<li>Vangard Labs Inc.</li>
<li>Vitrum Ab</li>
<li>Warner Lambert Company LLC</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>10 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>20 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>40 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>80 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB06274">Alvimopan</a></td><td>Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates. </td></tr><tr><td><a href="/drugs/DB00701">Amprenavir</a></td><td>Amprenavir may increase the serum concentration of atorvastatin by decreasing its metabolism. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>Atazanavir may increase the serum concentration of atorvastatin by decreasing its metabolism. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01393">Bezafibrate</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB08873">Boceprevir</a></td><td>Boceprevir increases the exposure of atorvastatin. Concomitant therapy should be closely monitored. </td></tr><tr><td><a href="/drugs/DB00559">Bosentan</a></td><td>Bosentan may decrease the serum concentration of atorvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if bosentan is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Carbamazepine, a p-glycoprotein inducer and strong CYP3A4 inducer, may decrease the effect of atorvastatin by increasing its efflux and metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if carbamazepine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>The macrolide, clarithromycin, may increase the toxicity of the statin, atorvastatin.</td></tr><tr><td><a href="/drugs/DB01394">Colchicine</a></td><td>Increased risk of rhadbomyolysis with this combination.</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Possible myopathy and rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00705">Delavirdine</a></td><td>Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if delavirdine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00343">Diltiazem</a></td><td>Diltiazem may increase the serum concentration of atorvastatin. Atorvastatin may increase the serum concentration of diltiazem. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.</td></tr><tr><td><a href="/drugs/DB04855">Dronedarone</a></td><td>Dronedarone is a CYP2D6 inhibitor thus increasing serum concentrations of atorvastatin. Lower doses of atorvastatin or consider rosuvastatin as cholesterol lowering therapy as there is no significant interaction between rosuvastatin and dronedarone. </td></tr><tr><td><a href="/drugs/DB00625">Efavirenz</a></td><td>Efavirenz may decrease the serum concentration of atorvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if efavirenz is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Eltrombopag increases levels of Atorvastatin via metabolism decrease.</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>The macrolide, erythromycin, may increase the toxicity of the statin, atorvastatin.</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Atorvastatin, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor continued efficacy of atorvastatin therapy. </td></tr><tr><td><a href="/drugs/DB01039">Fenofibrate</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB01319">Fosamprenavir</a></td><td>Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if fosamprenavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB02703">Fusidic Acid</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB01241">Gemfibrozil</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00619">Imatinib</a></td><td>Imatinib, a strong CYP3A4 inhibitor, may increase the effect and toxicity of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if imatinib is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB01321">Josamycin</a></td><td>The macrolide, josamycin, may increase the toxicity of the statin, atorvastatin.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB06655">Liraglutide</a></td><td>These agents may have decreased C max and a delayed T max during coadministration.</td></tr><tr><td><a href="/drugs/DB08827">Lomitapide</a></td><td>Atorvastatin, and other weak CYP3A4 inhibitors (such as amiodarone, amlodipine, alprazolam, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginko, goldenseal, isoniazide, lapatinib, nilotinib, oral contraceptives, pazopanib, ranitidine, ranolazine, tipranavir/ritonavir, ticagrelor, zileuton) increase lomitapide levels by 2-fold. Thus lomipatide should be dosed at a maximum of 30mg daily when used concomitantly with weak inhibitors of CYP3A4.</td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if nefazodone is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if nelfinavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00238">Nevirapine</a></td><td>Nevirapine, a strong CYP3A4 inducer, may decrease the serum concentration of atorvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if nevirapine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01369">Quinupristin</a></td><td>This combination presents an increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>Rifabutin may decrease the effect of atorvastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atorvastatin if rifabutin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin may decrease the effect of atorvastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atorvastatin if rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Ritonavir may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if ritonavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01232">Saquinavir</a></td><td>Saquinavir may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if saquinavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB05521">Telaprevir</a></td><td>Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>The macrolide antibiotic, telithromycin, may increase the serum concentration of atorvastatin by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atorvastatin if telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir, co-administered with Ritonavir, increases the adverse/toxic effects of Atorvastatin. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01030">Topotecan</a></td><td>The p-glycoprotein inhibitor, Atorvastatin, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Atorvastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce lovastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Atorvastatin if Verapamil is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if voriconazole is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Avoid drastic changes in dietary habit.</li>
<li>Avoid taking grapefruit or grapefruit juice throughout treatment. Grapefruit can significantly increase serum levels of this product.</li>
<li>Food may decrease maximum plasma levels and area under the curve, but this is clinically inconsequential according to the manufacturer.</li>
<li>Take with low fat meal.</li></ul></td></tr></tbody></table>